Alliqua Biomedical (ALQA) Upgraded at ValuEngine

ValuEngine upgraded shares of Alliqua Biomedical (NASDAQ:ALQA) from a hold rating to a buy rating in a research report report published on Wednesday.

ALQA stock traded down $0.07 during mid-day trading on Wednesday, hitting $1.67. 644 shares of the company were exchanged, compared to its average volume of 25,779. The firm has a market cap of $8.51 million, a PE ratio of -0.26 and a beta of 1.25. Alliqua Biomedical has a 12-month low of $1.55 and a 12-month high of $2.78.

Alliqua Biomedical (NASDAQ:ALQA) last announced its earnings results on Friday, August 10th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.64). The company had revenue of $0.86 million for the quarter. Alliqua Biomedical had a negative return on equity of 235.69% and a negative net margin of 90.48%. As a group, sell-side analysts anticipate that Alliqua Biomedical will post 5.14 EPS for the current fiscal year.

An institutional investor recently bought a new position in Alliqua Biomedical stock. FNY Investment Advisers LLC bought a new position in shares of Alliqua Biomedical Inc (NASDAQ:ALQA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 200,000 shares of the company’s stock, valued at approximately $454,000. FNY Investment Advisers LLC owned 3.99% of Alliqua Biomedical at the end of the most recent reporting period. 21.68% of the stock is currently owned by institutional investors.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.

Recommended Story: What is a Reverse Stock Split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with's FREE daily email newsletter.

Leave a Reply